VIRAL LOAD AND THE PCR
Why they can't be used to prove HIV infection
By Christine Johnson
Continuum Nov. 2001
"Biotechnology's version of the Xerox machine" -- that's
what Forbes magazine called the polymerase chain reaction (PCR). This
revolutionary technique enables a scientist to take a sample containing
a minute amount of DNA and replicate that DNA sequence until there are
a million copies instead of just one or two.
Kary Mullis, inventor of PCR, won a 1993 Nobel prize for his billion-dollar
invention, which has become indispensable to any genetics lab. It is ironic
that one of the first applications of PCR was to detect HIV, considering
that Mullis himself doesn't believe his invention is capable of this.
Mullis states the problem is PCR is too efficient -- it will amplify
whatever DNA is in the sample, regardless of whether that DNA belongs
to HIV or a contaminant. And how do you decide which part of the amplified
material could be HIV and which part the contaminant(s), if you couldn't
detect HIV in the sample without using PCR?
One of the main arguments against the HIV/AIDS hypothesis is that, when
employing traditional methods of virus detection, HIV has never been inferred
in significant amounts in people with AIDS. Virus culture, for instance,
has been adequate to find other viruses, but not HIV. Why not? When virus
culture is employed to detect HIV, HIV is never seen or even looked for
in the cultures. Its presence is measured by very indirect methods: assays
for detection of reverse transcriptase or a p24 protein, neither of which
is specific for HIV. Indirect methods would not be necessary if a significant
amount of HIV were there to begin with.
In other words, if a meaningful amount of HIV were present, the time-honoured
laboratory techniques should be able to find it. They can't. Now
we need not only PCR, but continuous modifications and improvements on
PCR, in order to try to find HIV.
This is how the idea of "viral load" came about, inspired by
two spates of scientific papers that claimed HIV is busily replicating
by the billions: initially, papers claiming HIV was "hiding in the
lymph nodes," (1,2) and more recently, the Ho and Wei papers. (3,4)
The latter studies attempted to measure "viral load" at a given
point, after which "antiviral" drugs were administered to the
patient. The drugs were supposed to prevent replication of any new HIV,
and the viral load would decrease accordingly. However, within a few days,
the remaining virus would mutate into a form resistant to the drugs, and
in a few weeks the viral load would return to its pre-treatment levels.
Applying a mathematical formula to this dynamic, the rate at which the
virus replicates was allegedly determined.
Hence was born what I call "Dr. Ho's kitchen sink theory".
According to Ho, billions of copies of HIV are being made every day, which
infect billions of T4-cells. These T-cells are destroyed not by HIV, but
by the immune system. They are replenished every day, but over the years,
the immune system loses ground and HIV finally wins. This process was
likened to a sink with the drain open, the water pouring in from a tap
(new T-cells being made) at a slightly lower rate than it drained away
(infected T-cells being destroyed).
It is most important to note that the viral load studies all rely completely
on PCR and related techniques. This article will discredit PCR as an accurate
method of determining HIV infection, which will in turn cast doubt on
any conclusions about HIV that have been made based on PCR techniques.
Some Basics On DNA
PCR takes advantage of certain fundamental properties of DNA. DNA (as
well as RNA) is a nucleic acid, and nucleic acids are composed of nucleotide
"building blocks". DNA exists as two complementary strands arranged
in a double helix formation (two intertwining spirals). These strands
are made up of many nucleotides hooked together to form a long chain of
The nucleotide molecule has three different parts: the phosphate and the
sugar (which form a backbone or a ribbon-like structure), and the base.
There are four types of bases: A, T, C, and G (adenine, thymine, cytosine,
and guanine). These bases are attached to the backbone, which is wound
in the familiar double helix.
The bases on one strand bind to the bases on the other strand, and this
gives DNA its stable double helix structure. (Think of the two strands
as forming a zipped-up zipper.) The distinct nature of an organism's
DNA code depends on the order, or sequence, of the bases along the DNA
There are special rules about how bases form chemical bonds with other
bases: an A will only bind to a T, and a C will only bind to a G. A base
on one strand binding to a base on the other strand is called a "complementary
base pair". This rule of complementary base pairing is what gives
DNA its ability to replicate itself exactly.
Each time a cell divides, it has to make a copy of its DNA for the new
cell. The DNA double-strand first "unzips" itself into two separate
strands. Each single strand serves as a template, or pattern, from which
to make a new copy of its complementary strand. (So, strand #1 serves
as a pattern to make a new copy of strand #2, and vice versa.) The single
strand then incorporates new nucleotide building blocks from the surrounding
medium according to the rule of complementary base pairing. In other words,
an available A on the single strand will grab onto a T nucleotide, a C
will grab a G, and so on until the entire opposite strand is duplicated.
At the end of this process, the two original strands zip themselves up
again, and the two copied strands serve as DNA for a new cell.
How PCR Works
The theory of HIV says it, like other suggested retroviruses, contains
RNA but no DNA: when HIV is said to infect a cell, the reverse transcriptase
enzyme is thought to transform the RNA into complementary DNA, which is
then inserted into the host cell's DNA.
Therefore, if PCR is used to analyse human tissue for the presence of
HIV, it would be looking for only a short segment out of the entire cellular
DNA strand. This short segment represents the genetic material proposed
for HIV, that in theory has been incorporated into the DNA of the cell.
(Viral load studies try to look for cell-free HIV. Even here, PCR is only
looking for part of HlV's entire proposed genetic package, or genome,
not an entire virus.)
PCR works in the following fashion:
Step 1: Heat the template.
A long piece of DNA containing the smaller fragment to be copied is heated.
The two strands can be "melted" apart at elevated temperatures,
and will slowly come back together upon cooling ("annealing").
The two separated strands are complementary to each other. They serve
as templates for the new strands.
Step 2: Add the primers. Something called a primer is necessary for
the next step. Primers are
nucleotides that form a short sequence of new strand. Primers are designed
to be complementary to a known sequence which is part of a larger sequence,
and thus where the primers will bind (or hybridise) is known.
The primers attach to each end of the DNA segment that is to be copied
(the segment that represents HIV's proposed genetic material). The
primers serve two purposes: a) to mark each end of the targeted segment
so only that segment will be amplified, and not the entire strand, and
b) to get the duplication process started. The new strands are built block
by block by the action of an enzyme called polymerase. The polymerase
builds a new DNA strand alongside an existing strand. The polymerase will
not work unless the old strand (the template) already has on it a few
nucleotides forming a short sequence of new strand (the primer). (If you
ever see a reference to "template-primers," this is what they're
In other words, the polymerase can only form a new strand if the new strand
has already partially been formed. In nature, when your own DNA is duplicating
itself, other enzymes called DNA primases build the primer onto the old
Once the polymerase gets going, it crawls along the single DNA strand
(the template) adding to it the nucleotide building blocks one by one.
The primer ends up being part of the newly-made strand.
In nature, polymerases pull the DNA strands apart while they build the
new DNA strand. This is how duplicate copies of DNA are made so that cells
like blood and skin cells can divide into two new cells, a process essential
Step 3: Amplify. Once again, after melting and then annealing the primers,
enzyme copies the DNA beginning at the primer, making a new copy of each
target segment. This process is repeated for as many as 30-40 rounds.
During each cycle, the amount of segments doubles, so two segments become
four, four become eight, then 16, etc. By the end of the process, approximately
a million copies of the original segment have been made. Now you have
a whole lot of DNA, where originally you had only a minuscule amount.
This is why PCR is referred to as being able to find a "needle in
Obviously, it is necessary for the primers to be specific to HIV. Whether
the PCR will make an amplified product (a "positive PCR") depends
on whether the primers you add match part of the DNA in the target specimen.
Below, we will see that the specificity of the primers for HIV is in doubt.
Even if the primers were specific to HIV, if similar sequences are present
in the target, the primers, under lax conditions, will form hybrids with (or bind) related sequences that are
less than a perfect match. They will then prime the polymerase, which starts the amplification procedure,
even though no HIV was present to begin with.
Using PCR To Find HIV
A problem for the HIV hypothesis was that, even with the use of standard
PCR, researchers could not find much, if any, HIV in persons with AIDS
diagnoses. To resolve this paradox, the authors of the new "viral
load" papers came up with two modifications of PCR, which they claimed
were much more efficient at finding HIV. These were the QC-PCR and the
branched DNA test (bDNA). And suddenly -- eureka! -- billions
of copies of what was believed to be HIV were found. The contradiction
here seems to have escaped the authors of these papers: Why would such
powerful new tests be needed at all to find a microbe that is present
in the billions? Traditional methods should suffice.
This is the test used in the above-mentioned papers by Anthony Fauci (Pantaleo)
and Ashley Haase (Embretson), which claimed HIV was "hiding in the
Iymph nodes." These papers were accepted as fact, even though QC-PCR
was, and remains, an unvalidated technique.
Mark Craddock, of the University of Sydney (Australia), explained the
principles of and problems with QC-PCR as follows: (8)
"PCR mass produces fragments of DNA. You start with a small amount
of DNA and after each PCR cycle, the amount of DNA you have is between
one and two times the amount at the beginning of the cycle. Thus, the
amount of DNA you have to study increases exponentially. The fact that
the PCR is an exponential growth process means that experimental errors
will also grow exponentially, so you need to be very careful about what
you do with the process.
"A number of people have decided that it should be possible to estimate
the amount of DNA present in a sample by using PCR. This is the so-called
quantitative competitive PCR. The idea is to add to the sample to be estimated
a known amount of similar but distinguishable DNA and amplify both together.
The assumption is that the relative amounts of the two products should
stay the same, and hence you can work out the size of the sample you started
with by knowing the ratio of the two, determined by observation when PCR
has produced enough of both to measure, and how much control DNA was added.
"What is absolutely crucial is that the relative amounts of the test
DNA and your known control must remain exactly equal. Close is not good
enough. The slightest variations will be magnified exponentially and can
produce massive errors in your estimate.
"The difficulties in using PCR quantitatively were pointed out by
Luc Raeymaekers in the journal Analytical Biochemistry in 1993. He noted
published papers on QC-PCR contain data that show that the fundamental
assumption that the relative sizes of the samples remain constant is not
met in practice. Despite this, HIV researchers continue to use PCR to
quantify viral load. There is simply no way of knowing whether a given
estimate is correct or is 100,000 times too high!"
Todd Miller calls QC-PCR the "latest fad in science" and agrees
that if the relative amounts of your test DNA and your known control are
not equal, there is one thing you can say for sure about the estimate
of your starting target (the amount of proposed HIV RNA in the patient's
blood sample): It will be wrong.
How did QC-PCR, with all its flaws, become an acceptable HIV test? Miller
explains: "The way this situation has manifested itself in modern science is
like this: First some people spend a lot of time trying to get this test
to work, and if they're lucky, end up publishing papers about caveats
in the procedure. Second, others happen to get the test to give them an
answer that "makes sense" and publish their data as a significant
contribution to the field. Third, because of its relative newness and
arcane nature, it remains as quasi-accepted with many passive sceptics
and a few users. However, most who use it are more interested in their
own pet phenomenon than in the mechanics of the reaction."
bDNA - BRANCHED DNA PCR
This is the test used in Ho's paper. Though it is not, strictly speaking,
PCR, it is referred to as such since it incorporates PCR-type technology.
The difference is that bDNA amplifies the signal, not the target. That
is, regular PCR makes more of the target so you can find it, whereas bDNA
sort of shines a bright spotlight on it so you can see it better. Project
Inform was kind enough to send me the following explanation of how bDNA
"Copies of a DNA probe are attached to the wall of a small laboratory
vessel; then the sample is put in. [A DNA probe is a small piece of DNA
complementary to the target DNA sequence.] This probe binds to a certain
part of HIV RNA, if it is found in the sample, holding the RNA in the
vessel. Then another DNA probe is put in; one end of this attaches to
another part of the HIV RNA. The other end of the second probe has many
branches and each branch ends with a "reporter" chemical that,
under certain conditions, will produce light, which can be detected by
laboratory equipment. Each molecule of HIV RNA can attach to one of these
branching structures and hold on to a small number of light sources, not
just one. In this way, very small amounts of the target RNA can be detected,
without the need for PCR amplification."
In his initial paper, Ho gave no data on the protocols for this test or
whether it was reliable. The reader was referred to two other papers that
were "in press". So, no data was available at that time to anyone
who wanted to verify this method. The data obtained from bDNA was confirmed
by QC-PCR, the details of QC-PCR being set out in a reference authored
by four co-authors of the Wei study, hardly what you might call independent
or objective researchers. In the tradition of HIV research, unproven theories
and faulty studies are accepted without question and incorporated into
the "conventional wisdom" before being properly validated. By
then, the damage is done, and if subsequent flaws are discovered it hardly
The mechanics of bDNA are complex: Five different hybridisation reactions
are going on. Hybridisation is a standard technique wherein a DNA probe
is put into a sample and will bind to any complementary segments it finds.
It's another indirect test, and it has a lot of problems. According
to molecular biologist Bryan Ellison, "The only time molecular biology
works is if you purify things first. There's always the possibility
of cross-reactions, especially when you put your probes into a big soup
of proteins" (which is exactly what the target blood sample is).
Duesberg pointed out the following: After making the appropriate adjustments
to his calculations, Ho himself later found that more than 10,000 viruses
inferred by the bDNA assay used in his Nature paper would actually correspond
to less than one infectious virus, leading one to wonder what it is that
is actually being measured on these tests. (10) Yet these speculative
and unvalidated papers have been accepted as gospel truth!
In Ellison's mind, Ho's study is "Pure fantasy. There's
never been a paper that shows viral load."
The Problems With PCR
1. THE ACCURACY OF PCR HAS NEVER BEEN VERIFIED BY A PROPER GOLD STANDARD
To find out if any diagnostic test for HIV infection actually works, it
is necessary to verify the test with an independent gold standard. The
only proper gold standard for this purpose is HIV itself. In other words,
the results of your experimental test, whether it's PCR or anything
else, must be compared to the results of virus isolation in each sample
tested. If virus is actually found in each patient with a positive PCR,
and no virus is found in each patient with a negative PCR, then you could
say PCR is extremely accurate for detecting HIV.
The concept of virus isolation as a gold standard is particularly important
in the case of HIV, since HIV has been extremely difficult, if not impossible,
to define in genetic or molecular terms. Even if anyone had ever accomplished
virus isolation for HIV (11), it has never been used as a gold
standard for any HIV diagnostic test, including PCR. As it stands right
now, bDNA uses QC-PCR as a gold standard; QC-PCR uses regular PCR as a
gold standard; regular PCR uses antibody tests as a gold standard, and
antibody tests use each other. I have noticed time after time that studies
which are "verifying" an HIV antibody test will invariably state
that they evaluated the performance of their test on samples which were
known to be TRUE-POSITIVE or TRUE-NEGATIVE. How did they know this? It's
simple: Without a gold standard, they didn't.
It is sometimes argued that "studies have shown" these tests
to agree with each other or confirm each other's findings, and therefore
they must be correct. This is not rigorous scientific thinking. Sometimes
you can get the results of different tests to agree with each other, but
that does not prove anything -- no more than it would prove if five
criminals all agreed that they were somewhere else when the bank was being
Eleopulos says the following about the importance of gold standards: "The
use of viral isolation as an independent means of establishing the presence
or absence of the virus is technically known as a gold standard, and is
a quintessential element for the authentication of any diagnostic test.
Without a gold standard, the investigator is hopelessly disoriented, since
he does not have an autonomous yardstick against which he can appraise
the test he is aspiring to develop.... Only by this means can we assure
patients that a positive HIV PCR is only ever found in the presence of
HIV infection, that is, the tests are highly specific for HIV infection."
Even well-known AIDS researcher William Blattner has conceded that "one
difficulty in assaying the specificity and sensitivity of human retrovirus
assays (including HIV) is the absence of a final 'gold standard.'
In the absence of gold standards for both HTLV-1 and HIV-1, the true sensitivity
and specificity for the detection of viral antibodies remain imprecise." (12)
Mark Craddock states QC-PCR is unverified and probably unverifiable. He
asks, "If PCR is the only way that the virus can be detected, then
how do you establish the precise viral load independently of PCR, so that
you can be certain that the figures PCR gives are correct?" All this
has apparently been lost on AIDS researchers, as it is regularly recommended
that PCR, particularly QC-PCR, be used as a gold standard for other HIV
2. THE SPECIFICITY OF PCR HAS NEVER BEEN DETERMINED
Specificity means how often a test will give negative results in people
who are not infected. A test's specificity rating reveals the level
of false-positive results to expect when using that test. Without a virus
isolation gold standard, the true specificity will never be known. Even
using concordance with antibody tests as a gold standard, PCR was not
found to be very specific for HIV. (6 )
Citing a proficiency study involving five laboratories with extensive
PCR experience, Sloand states that the average specificity was 94.7%. (14)
Specificity was as low as 90%. Numbers in the 90s may sound good, but
in reality, this is not the case. The number of false-positives compared
to true positives is dependent on the prevalence of HIV infection in any
population being tested (15) -- the lower the prevalence,
the more false-positives.
Sloand comments that if the specificity levels achieved in this study
were applied to the potential blood donor population" (blood donors
now consisting of members of the low-prevalence general population), then
"...for every true silent infection detected, 1800 uninfected donors
would be classified as PCR positive and 3500 as PCR indeterminate. Thus
PCR is clearly not suitable for routine screening of transfused blood"
and by inference, any low-prevalence population. At a specificity of 90%,
I would say it wasn't suitable for testing any population.
In a FAX I received from the Centers for Disease Control (CDC) in 1994
regarding PCR, they stated that "Neither its specificity nor its
sensitivity is known," and that "PCR is not recommended and
is not licensed for routine diagnostic purposes." (16)
In a nutshell, "The specificity of any form of PCR, for the HIV genome,
has not been determined." (5)
3. PCR PRIMERS ARE NOT SPECIFIC
According to Eleopulos, Turner, and Papadimitriou, "The minimum requirement
for [interpreting that a positive PCR signal, or hybridisation in general,
proves HIV infection] is prior proof that the PCR primers and the hybridisation
probes belong to a unique retrovirus, HIV, and that the PCR and hybridisation
reactions are HIV-specific." Turner told me: "The PCR genomic
arguments require isolation of HIV as absolutely essential. Otherwise
how does anyone know the origin of the nucleic acid?"
Eleopulos disputes the reality of a distinct HIV genome. Conceding its
existence for the sake of argument, she offers the following evidence
to demonstrate PCR is nonspecific for HIV: (17)
* There is no way to be sure the "HIV" nucleic acid probes
and PCR primers are specific to HIV because: most, if not all, probes
used for hybridisation assays, including the PCR probes and primers, are
obtained from "HIV" grown in tissue cultures using cells (called
a cell line) taken from a patient with T4 cell leukemia, a disease which
Gallo claims is caused by a retrovirus similar to HIV -- HTLV-I. And
recently a retrovirus is claimed to have been isolated from a non-HIV-infected
cell culture using another cell line. Thus the standard cell lines used
to grow HIV have been shown to indicate other retroviruses. Since even
the well-established method for isolating retroviruses (which to date
has never been done for HIV) cannot distinguish one retrovirus from another,
one cannot be confident that "HIV" nucleic acid probes and PCR
primers are indeed specific for HIV.
* Proposed HIV genes hybridise with the structural genes of HTLV-I
and HTLV-II, two other human retroviruses. This means that if the probes
find genetic material from these other retroviruses, they will stick to
it and give a signal that they have found HIV instead. Since it is accepted
that 10% of AIDS-diagnosed patients carry HTLV-I and that the normal human
genome contains sequences related to HTLV-I and HTLV-II, this type of
cross-reaction can be anticipated.
* Normal human cells contain hundreds or thousands of retrovirus-like
sequences, that is, small stretches of DNA that match a small part of
the proposed genome of HIV or other retroviruses. And, since PCR often
amplifies just a small part of the entire genome of whatever it's
looking for, how do you know that what it finds isn't a normal cellular
gene sequence that just happens to match part of what's proposed
* Further evidence that PCR is nonspecific is that positive PCRs
can be obtained from cells without nucleic acids. So if there's no
nucleic acid, there's no DNA or RNA, and if there's no DNA or
RNA, there's certainly no HIV.
* The chemicals used in labs in the preparation of tissue cultures
(called buffers and reagents) may give positive PCR signals for HIV. (18
4. PCR DETECTS ONLY A SMALL FRAGMENT OF AN ENTIRE VIRUS
PCR detects at best single genes and most often, only bits of genes. If
PCR finds two or three genetic fragments out of a possible dozen complete
genes, this is not proof that all the genes (the entire genome) are present.
Part of a gene does not equal a complete virus particle.
HIV experts admit that the majority of proposed HIV genomes are incomplete;
they could never orchestrate the synthesis of a virus particle.
Turner explains: "Even if all genomes were complete, having the plans
doesn't mean you've built the house. You can carry a whole retroviral
genome around inside your cells all your life without ever making a virus
particle." These two problems make it even more uncertain what the
significance of a positive PCR is.
5. THE FINDING OF "HIV RNA" ON PCR DOES NOT SIGNIFY THE PRESENCE
These days, one keeps hearing the phrase "HIV RNA PCR." What's
the difference between that and regular old DNA PCR? Regular PCR looks
for the DNA version of what is often accepted to be the HIV genome; RNA
PCR looks for the RNA version, that is, free virus that has not infected
With the new notion that HIV was busily replicating by the billions, it
was now thought necessary to find how much free virus there might be at
any given time. Free virus would contain only RNA, so if the PCR finds
a lot of "HIV RNA," it is believed billions of copies of free
virus are swarming around the patient's tissues. In other words,
if you find RNA, you've found HIV as well. Since it's believed
HIV contains two strands of RNA, the suggested formula is: Two RNAs =
In actuality, things are not this simple. In 1993, during the "HIV
is hiding in the lymph nodes" phase of the viral load theory, Piatak
and colleagues, including Shaw, admitted that in order to determine the
quantity of HIV particles, one must have prior evidence that the RNA actually
belongs to an HIV particle. (5) No such evidence was presented.
No relationship has yet been established between the amount of RNA and
the amount of particles that may or may not be present. And no one has
established whether the RNA comes from a virus particle or from somewhere
else. Without virus isolation, how do you know the origin of the nucleic
6. CELL-FREE VIRUS IS NOT INFECTIOUS VIRUS
Even if Ho were right about billions of cell-free HIVs being present in
the bloodstream, free virus is by definition not infectious virus; it's
irrelevant as a pathogen. For HIV to infect a cell, its envelope protein,
gp120, must bind to the CD4 receptor site on the cell's surface.
However, as far back as 1983, Gallo pointed out that "the viral envelope
which is required for infectivity is very fragile. It tends to come off
when the virus buds from infected cells, thus rendering the particles
incapable of infecting new cells." Because of this, Gallo said "cell-to-cell
contact may be required" for retroviral infection. Since gp120 is
"crucial to HlV's ability to infect new cells," and since
gp120 is not found in the cell-free particles, even if huge amounts of
free HIV are present in the blood, they would be non-infectious. (17)
7. PCR IS NOT STANDARDISED OR REPRODUCIBLE
In a recent paper, Teo and Shaunak commented on in situ PCR: "Despite
considerable effort, the technique is still technically difficult and
has not yet proved to be reliable or reproducible." (19)
In a study which compared PCR results to antibody test results, PCR was
found not to be reproducible and "False-positive and false-negative
results were observed in all laboratories (concordance with antibody tests
ranged from 40% to 100%)." (20)
8. PCR IS SUSCEPTIBLE TO CROSS-CONTAMINATION
Minute quantities of nucleic acids from prior specimens can easily contaminate
the specimen currently being tested, giving a false-positive result. (21)
Even microscopic bits of skin or hair from the lab technician can cause
this problem. Many sources of cross-contamination exist, and it can occur
"at any step in the procedure, from the point of collection of samples
through to the final amplification..." (22)
Other causes of false-positives are enumerated by Teo and Shaunak: "We
have now identified a number of factors which can contribute to the poor
amplification of the target DNA and to the generation of false-positive
signals. These factors include the effects of fixation, reagent abstraction,
DNA degradation, DNA end-labelling and product diffusion.... We believe
considerable caution should be exercised in the interpretation of results
generated using PCR in situ." (19)
9. FALSE-POSITIVES FREQUENTLY OCCUR WITH PCR
* A proficiency study to rate HIV PCR's performance on detecting
cell-free DNA showed "a disturbingly high rate of nonspecific positivity"
using the commonly employed primers (SK38/39, for the gag or p24 gene).
In fact, similar rates of positivity were found for both antibody-negative
and antibody-positive specimens (18% versus 26%)! (23)
* Out of 30 uninfected children, 6 had "occasional" positive
PCR results. (24)
* PCR performed on uninfected infants under one year of age showed
9/113 (9 out of 113), 15/143, 13/137, 7/87, and 1/63 infants to have positive
PCR tests. (25)
* Among 117 uninfected children born to HIV-infected mothers, six
(5%) had a false-positive PCR on cord blood. (26)
* In a PCR proficiency study, 54% of the laboratories involved had
problems with false-positive results; 9.3% of the total uninfected specimens
were reported as positive. (22)
* One out of 69 antibody-negative, non-seroconverters was PCR positive. (27)
* A high-risk individual was initially PCR positive but negative
on repeat PCR testing of the same specimen by two different laboratories. (27)
* The World Health Organisation's PCR working group demonstrated
high levels of false-positive results obtained during "blind"
HIV PCR studies. (22)
* Sheppard et al. stated in their study: "This trial demonstrated
that false-positive results, even with rigorous testing algorithms, occur
with sufficient frequency among uninfected individuals to remain a serious
* Out of 327 health care workers exposed by needlestick to HIV, 4
had one or more positive PCR results and 7 had indeterminate results.
Later samples for all 11 were negative and none seroconverted or developed
p24 antigenemia, leading to the conclusion that "false-positive results
occur even under the most stringent test conditions." (29)
Essential to Dr. Ho's theory is the idea that HIV mutates so rapidly
that within days or weeks it has become resistant to whatever "antiviral"
drug the patient is taking. In order to prevent this, it is recommended
that the patient take three-drug "combos" which theoretically
hit HIV from all angles simultaneously, thus reducing the chance that
a resistant strain will survive. Meanwhile, one must continuously monitor
the "viral load" with tests that cost 200 bucks a pop. Emphasis
is placed on early intervention, that is, dose patients with multi-drugs
the minute they sero-convert (assuming that anyone would know when this
event took place to begin with) and keep them on these drugs for the rest
of their lives.
Even though no one has shown them to be accurate, viral load assays are
being vigorously promoted as state-of-the-art necessities for PWAs, and
it's not hard to figure out why. In the Washington Post (2-06-96),
David Brown inadvertently revealed the reason: "Aggressive HIV treatment
will probably be even more expensive than in the past. Measuring viral
load will cost about $200 per test, and the new generation of HIV medicines
will probably be at least as expensive as the ones they replace."
U. S. News and World Report (2-12-96) was more specific, estimating the
yearly cost of a protease inhibitor at around $6,000, and the cost of
triple-drug combinations at up to $12,000 to $18,000. Combos of three
or four drugs are now prescribed, where one (AZT) used to suffice. As
more and more drugs are considered necessary to "treat" people,
many of whom have nothing wrong with them, it is obvious what a cash cow
this is going to be for the pharmaceutical industry.
The viral load theory has created a new worry to produce unbearable stress
in the lives of desperate people. It is now said that a person has only
one shot at the new "anti-viral" drugs, chiefly the protease
inhibitors. If you don't take them at exactly the right time, in
exactly the right combinations or amounts, or if you foolishly take only
one drug at a time, or lower your dose because the current dose is making
you sick, your virus will become resistant and the drugs will never work
on you again. And you can't just quit the drugs either, for the same
reason, even if they are making you deathly ill.
Every article on the subject so far has a different expert guess about
how this whole program is supposed to work: no one knows if you can get
cured or merely hold the line; no one knows the long-term prognosis for
those who take this triple-toxic triple-combo. (Protease inhibitors have
produced extreme adverse reactions in many people, so it shouldn't
be hard to figure it out). Anyone foolish enough to sign up will become
a test animal for people who don't know what they're doing.
When will we stop allowing ourselves to be used as guinea pigs for whatever
crack-brained scheme comes down the pike? When will we put a lock on our
wallets and refuse to pay for the privilege of being poisoned? And when
will we quit supporting the most degraded human beings in existence --
those who profit from the suffering of others?
Christine Johnson is a member of MENSA and a freelance science journalist from Los Angeles, USA. She is the Contact person of HEAL/Los Angeles, is on the Board of Advisors of Continuum magazine and copy-editor of Reappraising AIDS. She has an extensive background in medicine, law and library research and is motivated by a desire to find out the truth about 'AIDS'. She has a special interest in making the information in technical science journals accessible to the public. Over the past four years she has followed the work of the Perth group and written articles critical of the HIV antibody tests, including an extensive interview with Eleni Papadopulos-Eleopulos, which have been published world-wide.
1. Embretson J, Zupancicl M, Ribas JL, et al. 1992. "Massive covert
infection of helper T lymphocytes and macrophages by HIV during the incubation
period of AIDS." Nature. 362:359-362.
2. Pantaleo G, Graziosi C, Demarest J, et al. 1993. "HIV infection
is active and progressive in lymphoid tissue during the clinically latent
stage of disease." Nature. 362:355-358.
3. Ho DD, Neumann AU, Perelson AS, et al. 1995. "Rapid turnover of
plasma virions and CD4 lymphocytes in HIV-1 infection." Nature. 373:123-126.
4. Wei X, Ghosh SK, Taylor ME, et al. 1995. "Viral dynamics in human
immunodeficiency virus type 1 infection." Nature. 373:117-122.
5. Eleopulos E, Turner VF, Papadimitriou J. 1995. "Turnover of HIV-1
and CD4 lymphocytes." Reappraising AIDS. 3(6):2-4.
6. Eleopulos E, Turner VF, Papadimitriou J. Letter to Nature. 1994. "Is
HIV really hiding in the Iymph nodes?"
7. Duesberg P, Bialy H. "Responding to 'Duesberg and the new
view of HIV"' in AIDS: Virus- or Drug-Induced. Kluwer Academic
Publishers, Boston (1996).
8. Craddock M. 1995. "HIV: Science by Press Conference." Reappraising
9. Project Inform Fact Sheet: PCR Tests. August 1, 1995.
10. Duesberg P, Bialy H. 1995. "HIV an illusion." Nature. 375:197.
11. Papadopulos-Eleopulos E, Turner VF and Papadimitriou JM. 1993. "Is
a positive Western Blot proof of HIV infection?" Bio/Technology.
12. Blattner WA. 1989. Retroviruses. pp545-592. In Viral Infections in
Humans, third edition, edited by A Evans. Plenum Medical Book Company,
13. Macy E, Adelman D. 1988. Letter to New England Journal of Medicine.
14. Sloand E, Pitt E, Chiarello R, et al. 1991. "HIV Testing: State
of the art." JAMA. 266:2861.
15. Maver, Robert. April 1993. "Testing AIDS Tests." Rethinking
16. Centers for Disease Control Faxback document #320320, January 1993.
17. Eleopulos E, Turner VF, Papadimitriou J, Causer D. 1995. "Factor
Vlll, HIV, and AIDS in hemophiliacs: An analysis of their relationship."
18. Conway B. 1990. "Detection of HIV-1 by PCR in Clinical Specimens,"
p40-45, in Techniques in HIV Research, edited by A Aldovini and BD Walker,
MacMillan, New York.
19. Teo IA, Shaunak S. 1995. "PCR in situ: aspects which reduce amplification
and generate false-positive results." Histochem. J. 27:660.
20. Defer C, Agut H, Garbarg-Chenon A, et al. 1992. "Multicentre
quality control of polymerase chain reaction for detection of HIV DNA."
21. Bootman JS, Kitchin PA. 1994. "Reference preparations in the
standardization of HIV-1 PCR: An international collaborative study."
J. Vir. Meth. 49:1-8.
22. Bootman JS, Kitchin PA. 1992. "An international collaborative
study to assess a set of reference reagents for HIV-1 PCR." J. Vir.
23. Busch MP, Henrard DR, Hewlett IK, et al. 1992. "Poor sensitivity,
specificity, and reproducibility of detection of HIV-1 DNA in serum by
polymerase chain reaction." J. AIDS. 5:872.
24. Garbarg-Chenon A, Segondy M, Conge A, et al. 1993. "Virus isolation,
polymerase chain reaction and in vitro antibody production for the diagnosis
of pediatric human immunodeficiency virus infection." J. Vir. Methods.
25. Paui MO, Tetali S, Lesser ML, et al. 1996. "Laboratory diagnosis
of infection status in infants perinatally exposed to human immunodeficiency
virus type 1." J. Inf. Dis. 173:68.
26. Simonon A, Lepage P, Karita E, et al. 1994. "An assessment of
the timing of mother-to-child transmission of human immunodeficiency virus
type 1 by means of polymerase chain reaction." J. AIDS. 7:952.
27. Celum CL, Coombs RW, Lafferty W, et al. 1991. "Indeterminate
human immunodeficiency virus type 1 Western Blots: Seroconversion risk,
specificity of supplemental tests, and an algorithm for evaluation."
J. Inf. Dis. 164:656.
28. Sheppard HW, Ascher MS, Busch MP, et al. 1991. "A multicenter
proficiency trial of gene amplification (PCR) for the detection of HIV-1."
J. AIDS. 4:277.
29. Gerberding JL. 1994. "Incidence and prevalence of human immunodeficiency
virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among
health care personnel at risk for blood exposure: Final report from a
longitudinal study." J. Inf. Dis. 170:1410.
With acknowledgements to: Paul Philpott, former research assistant in
immunology and current editor of Reappraising AIDS; and Todd Miller,
Ph.D. in biochemistry and molecular biology, of the University of Miami.
A similar version of this piece first appeared in the HEAL/New York
Bulletin, Oct. 1996